Summary of Research: Bullous Pemphigoid Burden of Disease, Management and Unmet Therapeutic Needs

This is a summary of the original review article “Bullous Pemphigoid: Burden of Disease, Management and Unmet Therapeutic Needs.” Bullous pemphigoid (BP) is a rare, chronic, autoimmune blistering disease that primarily affects older adults. It is a potentially life-threatening disease that can negatively impact patients’ quality of life. In this research summary, we provide an overview of this disease progression, how it can be diagnosed (including the diagnostic tools available), and what comorbidities might accompany it in this vulnerable population. In addition, we discuss the measures used to assess disease severity, as well as the standard-of-care treatment. Potential new biologics under investigation are also discussed.

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2026-11-21
DOI
https://doi.org/10.1007/s13555-026-01972-y
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Summary of Research: Bullous Pemphigoid Burden of Disease, Management and Unmet Therapeutic Needs

Dedee Frances Murrell, Victoria P. Werth, Marius Ardeleanu, Pascal Joly et al.
Dermatology and Therapy
Autoimmune Bullous Skin Diseases
article

Summary of Research: Bullous Pemphigoid Burden of Disease, Management and Unmet Therapeutic Needs

Dedee Frances Murrell, Victoria P. Werth, Marius Ardeleanu, Pascal Joly, Marc Yale, Verena Hultsch
article en

Abstract

This is a summary of the original review article “Bullous Pemphigoid: Burden of Disease, Management and Unmet Therapeutic Needs.” Bullous pemphigoid (BP) is a rare, chronic, autoimmune blistering disease that primarily affects older adults. It is a potentially life-threatening disease that can negatively impact patients’ quality of life. In this research summary, we provide an overview of this disease progression, how it can be diagnosed (including the diagnostic tools available), and what comorbidities might accompany it in this vulnerable population. In addition, we discuss the measures used to assess disease severity, as well as the standard-of-care treatment. Potential new biologics under investigation are also discussed.

Dermatology and Therapy
Inserm (FR), Regeneron (United States) (US), UNSW Sydney (AU), Cancer Trials Australia (AU), St George Hospital (AU), Philadelphia VA Medical Center (US), International Pemphigus & Pemphigoid Foundation (US), Université de Rouen Normandie (FR), University of Pennsylvania (US)
Autoimmune Bullous Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon